Livestream: A CaseWise™ Initiative – Cracking Complex Cases: Following New IL-23 Evidence to Individualize Care in IBD

The treatment landscape for inflammatory bowel disease (IBD) has entered an exciting new era of precision medicine, as innovative therapies such as interleukin-23 (IL-23) inhibitors offer renewed hope for sustained remission and improved quality of life. Rapidly emerging clinical trial data, evolving guidelines, and a growing array of biologic and small-molecule therapies present complex challenges for clinicians, who must navigate differences in mechanisms of action, administration routes, and optimal treatment positioning. Despite recommendations supporting earlier initiation of advanced therapies, gaps in clinician knowledge and confidence often delay adoption of innovative treatments – delays that patients with difficult-to-treat IBD presentations, particularly perianal fistulizing disease, cannot afford. Clinicians and multidisciplinary care teams need best-in-class, evidence-based education that bridges the gap between emerging science and real-world practice, translating the latest evidence into actionable therapeutic selection strategies and personalized care for people living with IBD.

This fast-paced and highly interactive livestream CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will evaluate the latest efficacy and safety data for the IL-23p19 inhibitor class, including evidence in fistulizing and biologic-refractory disease, and integrate these findings and current guidelines into treatment selection for people with complex or difficult-to-treat IBD. Expert faculty will model the application of current IL-23p19 class evidence to real-world decisions in complex IBD cases involving prior treatment failure, comorbidities, or extraintestinal manifestations. Informed by the perspectives of expert faculty, key opinion leaders, community clinicians, and people living with IBD, learners will be better equipped to develop individualized, patient-centered treatment plans that apply shared decision-making to the goals, quality of life priorities, and access barriers of people with challenging IBD presentations.

At the conclusion of this activity, learners will be able to better:

• Integrate the latest efficacy, safety, and guideline data for the IL-23p19 inhibitor class into treatment selection for patients with complex or difficult-to-treat IBD, including fistulizing and biologic-refractory disease
• Develop individualized, patient-centered treatment plans that apply SDM to the goals, QoL priorities, and access barriers of patients with challenging IBD presentations
• Evaluate the latest clinical trial efficacy and safety data for recently approved IL-23p19 inhibitors, including evidence in fistulizing and other high-unmet-need populations
• Apply current IL-23p19 class evidence to real-world decisions in complex IBD cases involving prior treatment failure, comorbidities, or extra-intestinal manifestations

Supported by an educational grant from Johnson & Johnson.

Gastroenterologists, physician associates (PAs), and nurse practitioners (NPs)

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Barnes reports the following financial relationships:

Advisory Board: AbbVie Inc; Celltrion, Inc.; Johnson & Johnson; and Lilly

Consultant: Boomerang Medical, Inc.; Cristcot LLC; Merck & Co., Inc.; Pathways GI; Pfizer Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Target RWE

Research Support: Bausch Health Companies Inc/Salix Pharmaceuticals, Inc.; and Lilly

Dr. Abraham reports the following financial relationships:

Consultant: Abbvie Inc.; Abivax SA; Biocon Limited; Boehringer Ingelheim International GmbH; Canon Inc.; Celltrion, Inc.; Ironwood Pharmaceuticals, Inc.; Johnson and Johnson; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; F. Hoffmann-La Roche Ltd, Sanofi S.A.; and Takeda Pharmaceutical Company Limited

Research Support: Abivax; SA; and Lilly

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Shirley Michelle Franks, DNP, APRN, FNP-BC, PMC MSN Ed (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Leah Zadrozny, DVM, PhD (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

MMS-171-012227-57